About Innocoll

Innocoll is a biotherapeutics pharmaceutical company committed to improving the status quo and finding answers to unmet needs

XARACOLL® (bupivacaine HCl) Implant

Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020

Latest News

Innocoll Announces Positive Topline Results for Xaracoll® (Bupivacaine Hydrochloride) Implant in a Phase 3 Study to Support Expanded Use

XARACOLL 300mg Dose Cohort Experienced Less Pain and XARACOLL was Generally Well Tolerated with an Adverse Event Profile Comparable to...
Read More

Innocoll Announces Co-Promotion Agreement for Hernia Product Portfolio

Positions Innocoll as a comprehensive hernia solutions company including products for surgery and open inguinal hernia repair pain relief Innocoll...
Read More

Innocoll Announces Successful Completion of Debt Refinancing

$125 million refinancing substantially improves Innocoll’s liquidity, enabling further investment in pharmaceutical technology portfolio and growth plan ATHLONE, Ireland –...
Read More